Overview

HYPERTONIC SALINE IN ACUTE VIRAL BRONCHIOLITIS: A RANDOMIZED CLINICAL TRIAL

Status:
Withdrawn
Trial end date:
2014-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether nebulized hypertonic saline solution reduces the admission rate 48 hours after initial treatment in the emergency department, when compared to normal saline solution (placebo). We hypothesise that patients with bronchiolitis who receive nebulized hypertonic saline solution will have less respiratory distress, less duration of symptoms and therefore less risk of being hospitalized than those receiving normal saline solution.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Laval University
Collaborators:
Canadian Institutes of Health Research (CIHR)
Centre de Recheche du Centre Hospitalier Université Laval
Treatments:
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- clinical diagnosis of viral bronchiolitis

- Age 6 weeks to 12 months

- Clinical Score IRAS >3 and <8

Exclusion Criteria:

- prematurity <30 weeks

- younger than 6 weeks of age

- chronic lung disease

- immunosuppression.

- History of wheezing or asthma.

- Clinical Score IRAS >9

- parents refuse study